ReviewMinerva gastroenterologica e dietologica2012
Diabetes and pancreatic cancer.
Review in Minerva gastroenterologica e dietologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research.Frontiers in pharmacology · 2025Review
- Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024Review
- Earlier Diagnosis of Pancreatic Cancer: Is It Possible?Cancers · 2023Review
- Sugar Sweetened and Artificially Sweetened Beverage Consumption and Pancreatic Cancer: A Retrospective Study.Nutrients · 2023Article
- Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene.Frontiers in cell and developmental biology · 2022Review
- Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other Cancers.Pharmaceutics · 2021Review
- Russian Consensus on Exo- and Endocrine Pancreatic Insufficiency After Surgical Treatment.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication.Molecular cancer · 2021Review
- Observational
- Updated risk factors to inform early pancreatic cancer screening and identify high risk patients.Cancer letters · 2020Article
- The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives.Journal of cellular and molecular medicine · 2020Review
- Diabetes and cancer: Epidemiological and biological links.World journal of diabetes · 2020Review
- MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators.BMC cancer · 2019Review
- Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.Pathology oncology research : POR · 2019Review
- Pancreatic Cancer and Diabetes Mellitus.Current treatment options in gastroenterology · 2018Review
- The Dual Role of HMGB1 in Pancreatic Cancer.Journal of pancreatology · 2018Article
- Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey.Internal and emergency medicine · 2018Observational
- Long-term patterns of fasting blood glucose levels and pancreatic cancer incidence.Cancer causes & control : CCC · 2018Article
- Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells.Journal of proteome research · 2017Article
- Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.The American journal of gastroenterology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The relationship between diabetes and pancreatic cancer is complex. Diabetes or impaired glucose tolerance is present in more than 2/3rd of pancreatic cancer patients. Epidemiological studies have consistently shown a modest increase in the risk of pancreatic cancer in type 2 diabetes, with an inverse relationship to duration of disease. Additionally, recent studies suggest that anti-diabetic medications may modulate the risk of pancreatic cancer in type 2 diabetes. Subjects >50 years of age with new onset diabetes are at higher risk of having pancreatic cancer. However, to screen new-onset diabetes for pancreatic cancer, additional markers are needed that can distinguish pancreatic cancer-associated diabetes from type 2 diabetes.
Indexed as
Identifiers
23207610PMC3932318W1608137176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.